Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs. According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s global head of corporate affairs for oncology—has been charged with taking advantage of his advance knowledge of the 2019 deal to buy $20,000 worth of stock. Joublin became aware of AZ’s impending deal to acquire commercial rights to Daiichi Sankyo’s breast cancer drug Enhertu on March 6, 2019, the filing alleges; six...…Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs. According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s global head of corporate affairs for oncology—has been charged with taking advantage of his advance knowledge of the 2019 deal to buy $20,000 worth of stock. Joublin became aware of AZ’s impending deal to acquire commercial rights to Daiichi Sankyo’s breast cancer drug Enhertu on March 6, 2019, the filing alleges; six...WW…